{"id":6708,"date":"2025-11-05T07:05:39","date_gmt":"2025-11-05T00:05:39","guid":{"rendered":"https:\/\/regular-investor.com\/?p=6708"},"modified":"2025-11-05T07:05:44","modified_gmt":"2025-11-05T00:05:44","slug":"pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global","status":"publish","type":"post","link":"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/","title":{"rendered":"PYFA Catat Pendapatan Rp2,06 Triliun di Kuartal III-2025, EBITDA Naik 100% Didukung Ekspansi Global"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\">Kinerja PYFA Melesat di Kuartal III-2025: Pendapatan Naik 77%, EBITDA Tumbuh 100%<\/h3>\n\n\n\n<p>PT <strong>Pyridam Farma Tbk (PYFA)<\/strong> mencatat <strong>pendapatan konsolidasi sebesar Rp2,06 triliun<\/strong> hingga akhir <strong>kuartal III-2025<\/strong>, melonjak <strong>77,3%<\/strong> dibandingkan periode yang sama tahun sebelumnya sebesar Rp1,16 triliun. Lonjakan ini turut mendorong <strong>EBITDA naik 100,6% YoY<\/strong> menjadi <strong>Rp133,32 miliar<\/strong> dari Rp66,44 miliar.<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cBisnis inti Perseroan, termasuk kontribusi dari entitas baru, tetap berjalan kuat dan efisien,\u201d ujar <strong>Sinta Ningsih<\/strong>, Direktur Keuangan PYFA, Selasa (4\/11\/2025).<\/p>\n<\/blockquote>\n\n\n\n<h3 class=\"wp-block-heading\">Laba Kotor Naik 41%, Efisiensi Terjaga di Tengah Ekspansi<\/h3>\n\n\n\n<p>Seiring ekspansi dan integrasi pasca-akuisisi, <strong>beban pokok penjualan<\/strong> tercatat sebesar <strong>Rp1,64 triliun<\/strong>. Meski meningkat, PYFA tetap menjaga efisiensi, terbukti dari:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Laba kotor<\/strong>: naik 41,28% YoY menjadi Rp417,86 miliar<\/li>\n\n\n\n<li><strong>Fundamental operasional<\/strong>: tetap solid dan terarah<\/li>\n<\/ul>\n\n\n\n<p>PYFA mengajak pemangku kepentingan untuk melihat <strong>gambaran besar<\/strong>, mengingat proses integrasi masih berlangsung dan potensi pertumbuhan ke depan sangat kuat.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Probiotec Australia dan Ethica Cikarang Jadi Motor Pertumbuhan<\/h3>\n\n\n\n<p>PYFA telah mengoptimalkan operasional pabrik <strong>Probiotec di Kemps Creek, Australia<\/strong>, yang kini beroperasi penuh sejak <strong>November 2025<\/strong>. Pabrik ini telah mengantongi:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Sertifikasi TGA (Therapeutic Goods Administration)<\/strong><\/li>\n\n\n\n<li><strong>Sertifikasi Halal AIHCO<\/strong><\/li>\n<\/ul>\n\n\n\n<p>Sertifikasi ini membuka <strong>akses ekspor global<\/strong> dan memperkuat posisi PYFA di pasar internasional. Di dalam negeri, pembangunan pabrik <strong>Ethica di Cikarang<\/strong> berjalan sesuai rencana dan ditargetkan rampung pada <strong>awal 2026<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Pilar Bisnis Menguat: CDMO, NCE, dan OTC<\/h3>\n\n\n\n<p>Pertumbuhan PYFA didorong oleh penguatan di seluruh pilar bisnis:<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">1. <strong>CDMO (Contract Development and Manufacturing Organization)<\/strong><\/h4>\n\n\n\n<p>PYFA menjalin kemitraan dengan berbagai principal farmasi global:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Eli Lilly (AS)<\/strong>: Cialis, Humalog, Humulin<\/li>\n\n\n\n<li><strong>Amgen (AS)<\/strong>: Corora, Amgevita, Xgeva<\/li>\n\n\n\n<li><strong>Lundbeck (Denmark)<\/strong>: Abixa, Brintellix, Vyepti<\/li>\n\n\n\n<li><strong>Merz Pharma (Jerman)<\/strong>: Xeomin, Hepamerz<\/li>\n\n\n\n<li><strong>Polysan (Rusia)<\/strong>: Reamberin, Cytoflavin<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">2. <strong>Obat Resep (Rx)<\/strong><\/h4>\n\n\n\n<p>Penjualan meningkat berkat portofolio produk inovatif, termasuk <strong>New Chemical Entity (NCE)<\/strong> pertama di Indonesia.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">3. <strong>Over-the-Counter (OTC)<\/strong><\/h4>\n\n\n\n<p>Melalui lini <strong>PYFAHealth<\/strong> dan <strong>PYFABeauty<\/strong>, produk unggulan kini tersedia di jaringan ritel terkemuka:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Century<\/li>\n\n\n\n<li>Boots<\/li>\n\n\n\n<li>Apotek Roxy<\/li>\n\n\n\n<li>VIVA Apotek<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Outlook 2026: Integrasi Strategis dan Pertumbuhan Berkelanjutan<\/h3>\n\n\n\n<p>Dengan operasional pabrik yang semakin optimal dan strategi integrasi yang berjalan sesuai rencana, PYFA siap menghadapi 2026 dengan:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prospek pertumbuhan yang solid<\/strong><\/li>\n\n\n\n<li><strong>Ekspansi global yang terukur<\/strong><\/li>\n\n\n\n<li><strong>Komitmen menciptakan nilai tambah berkelanjutan bagi pemegang saham<\/strong><\/li>\n<\/ul>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p>\u201cKami yakin prospek pertumbuhan yang solid di 2026. Perseroan berkomitmen menyelesaikan integrasi strategis ini,\u201d tutup Sinta.<\/p>\n<\/blockquote>\n","protected":false},"excerpt":{"rendered":"<p>Kinerja PYFA Melesat di Kuartal III-2025: Pendapatan Naik 77%, EBITDA Tumbuh 100% PT Pyridam Farma Tbk (PYFA) mencatat pendapatan konsolidasi sebesar Rp2,06 triliun hingga akhir kuartal III-2025, melonjak 77,3% dibandingkan periode yang sama tahun sebelumnya sebesar Rp1,16 triliun. Lonjakan ini turut mendorong EBITDA naik 100,6% YoY menjadi Rp133,32 miliar dari Rp66,44 miliar. \u201cBisnis inti Perseroan, [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":5244,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"_links_to":"","_links_to_target":""},"categories":[288],"tags":[4697,4695,3505,2809],"class_list":["post-6708","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market","tag-berita-investasi","tag-berita-saham","tag-pt-pyridam-farma-tbk","tag-pyfa"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PYFA Catat Pendapatan Rp2,06 Triliun di Kuartal III-2025, EBITDA Naik 100% Didukung Ekspansi Global - Regular-investor.com<\/title>\n<meta name=\"description\" content=\"PT Pyridam Farma Tbk (PYFA) membukukan pendapatan Rp2,06 triliun hingga kuartal III-2025, naik 77,3% YoY. EBITDA melonjak 100,6% didorong ekspansi pabrik Probiotec Australia dan penguatan segmen CDMO, NCE, serta OTC.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PYFA Catat Pendapatan Rp2,06 Triliun di Kuartal III-2025, EBITDA Naik 100% Didukung Ekspansi Global - Regular-investor.com\" \/>\n<meta property=\"og:description\" content=\"PT Pyridam Farma Tbk (PYFA) membukukan pendapatan Rp2,06 triliun hingga kuartal III-2025, naik 77,3% YoY. EBITDA melonjak 100,6% didorong ekspansi pabrik Probiotec Australia dan penguatan segmen CDMO, NCE, serta OTC.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/\" \/>\n<meta property=\"og:site_name\" content=\"Regular-investor.com\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/regularinvestorscom\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-05T00:05:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-05T00:05:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/02\/pyridam-farma-PYFA.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"801\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Septian\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@rinvestorcom\" \/>\n<meta name=\"twitter:site\" content=\"@rinvestorcom\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Septian\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/11\\\/05\\\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/11\\\/05\\\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\\\/\"},\"author\":{\"name\":\"Septian\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#\\\/schema\\\/person\\\/e0935cf1dd7abe3c6dc3ba60c4c6afbf\"},\"headline\":\"PYFA Catat Pendapatan Rp2,06 Triliun di Kuartal III-2025, EBITDA Naik 100% Didukung Ekspansi Global\",\"datePublished\":\"2025-11-05T00:05:39+00:00\",\"dateModified\":\"2025-11-05T00:05:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/11\\\/05\\\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\\\/\"},\"wordCount\":354,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/11\\\/05\\\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regular-investor.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/pyridam-farma-PYFA.webp\",\"keywords\":[\"berita investasi\",\"Berita Saham\",\"PT Pyridam Farma Tbk\",\"PYFA\"],\"articleSection\":[\"Market\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/11\\\/05\\\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/11\\\/05\\\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\\\/\",\"url\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/11\\\/05\\\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\\\/\",\"name\":\"PYFA Catat Pendapatan Rp2,06 Triliun di Kuartal III-2025, EBITDA Naik 100% Didukung Ekspansi Global - Regular-investor.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/11\\\/05\\\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/11\\\/05\\\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regular-investor.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/pyridam-farma-PYFA.webp\",\"datePublished\":\"2025-11-05T00:05:39+00:00\",\"dateModified\":\"2025-11-05T00:05:44+00:00\",\"description\":\"PT Pyridam Farma Tbk (PYFA) membukukan pendapatan Rp2,06 triliun hingga kuartal III-2025, naik 77,3% YoY. EBITDA melonjak 100,6% didorong ekspansi pabrik Probiotec Australia dan penguatan segmen CDMO, NCE, serta OTC.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/11\\\/05\\\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/11\\\/05\\\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/11\\\/05\\\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regular-investor.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/pyridam-farma-PYFA.webp\",\"contentUrl\":\"https:\\\/\\\/regular-investor.com\\\/wp-content\\\/uploads\\\/2025\\\/02\\\/pyridam-farma-PYFA.webp\",\"width\":1200,\"height\":801,\"caption\":\"PYFA\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/index.php\\\/2025\\\/11\\\/05\\\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/regular-investor.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PYFA Catat Pendapatan Rp2,06 Triliun di Kuartal III-2025, EBITDA Naik 100% Didukung Ekspansi Global\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#website\",\"url\":\"https:\\\/\\\/regular-investor.com\\\/\",\"name\":\"Regular-investor.com\",\"description\":\"You Sleep and Makes Money\",\"publisher\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#organization\"},\"alternateName\":\"R-INVESTOR\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regular-investor.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#organization\",\"name\":\"Regular-investor.com\",\"alternateName\":\"R-INVESTOR\",\"url\":\"https:\\\/\\\/regular-investor.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/regular-investor.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/cropped-Photoroom-20250309_055542.png\",\"contentUrl\":\"https:\\\/\\\/regular-investor.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/cropped-Photoroom-20250309_055542.png\",\"width\":512,\"height\":512,\"caption\":\"Regular-investor.com\"},\"image\":{\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/regularinvestorscom\",\"https:\\\/\\\/x.com\\\/rinvestorcom\",\"https:\\\/\\\/www.instagram.com\\\/regularinvestorcom\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regular-investor.com\\\/#\\\/schema\\\/person\\\/e0935cf1dd7abe3c6dc3ba60c4c6afbf\",\"name\":\"Septian\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/92a9de20d2caa2c476ece696d5c701129c727d67c38aec458c129ecec23aeb40?s=96&d=wavatar&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/92a9de20d2caa2c476ece696d5c701129c727d67c38aec458c129ecec23aeb40?s=96&d=wavatar&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/92a9de20d2caa2c476ece696d5c701129c727d67c38aec458c129ecec23aeb40?s=96&d=wavatar&r=g\",\"caption\":\"Septian\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PYFA Catat Pendapatan Rp2,06 Triliun di Kuartal III-2025, EBITDA Naik 100% Didukung Ekspansi Global - Regular-investor.com","description":"PT Pyridam Farma Tbk (PYFA) membukukan pendapatan Rp2,06 triliun hingga kuartal III-2025, naik 77,3% YoY. EBITDA melonjak 100,6% didorong ekspansi pabrik Probiotec Australia dan penguatan segmen CDMO, NCE, serta OTC.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/","og_locale":"en_US","og_type":"article","og_title":"PYFA Catat Pendapatan Rp2,06 Triliun di Kuartal III-2025, EBITDA Naik 100% Didukung Ekspansi Global - Regular-investor.com","og_description":"PT Pyridam Farma Tbk (PYFA) membukukan pendapatan Rp2,06 triliun hingga kuartal III-2025, naik 77,3% YoY. EBITDA melonjak 100,6% didorong ekspansi pabrik Probiotec Australia dan penguatan segmen CDMO, NCE, serta OTC.","og_url":"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/","og_site_name":"Regular-investor.com","article_publisher":"https:\/\/facebook.com\/regularinvestorscom","article_published_time":"2025-11-05T00:05:39+00:00","article_modified_time":"2025-11-05T00:05:44+00:00","og_image":[{"width":1200,"height":801,"url":"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/02\/pyridam-farma-PYFA.webp","type":"image\/webp"}],"author":"Septian","twitter_card":"summary_large_image","twitter_creator":"@rinvestorcom","twitter_site":"@rinvestorcom","twitter_misc":{"Written by":"Septian","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/#article","isPartOf":{"@id":"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/"},"author":{"name":"Septian","@id":"https:\/\/regular-investor.com\/#\/schema\/person\/e0935cf1dd7abe3c6dc3ba60c4c6afbf"},"headline":"PYFA Catat Pendapatan Rp2,06 Triliun di Kuartal III-2025, EBITDA Naik 100% Didukung Ekspansi Global","datePublished":"2025-11-05T00:05:39+00:00","dateModified":"2025-11-05T00:05:44+00:00","mainEntityOfPage":{"@id":"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/"},"wordCount":354,"commentCount":0,"publisher":{"@id":"https:\/\/regular-investor.com\/#organization"},"image":{"@id":"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/#primaryimage"},"thumbnailUrl":"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/02\/pyridam-farma-PYFA.webp","keywords":["berita investasi","Berita Saham","PT Pyridam Farma Tbk","PYFA"],"articleSection":["Market"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/","url":"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/","name":"PYFA Catat Pendapatan Rp2,06 Triliun di Kuartal III-2025, EBITDA Naik 100% Didukung Ekspansi Global - Regular-investor.com","isPartOf":{"@id":"https:\/\/regular-investor.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/#primaryimage"},"image":{"@id":"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/#primaryimage"},"thumbnailUrl":"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/02\/pyridam-farma-PYFA.webp","datePublished":"2025-11-05T00:05:39+00:00","dateModified":"2025-11-05T00:05:44+00:00","description":"PT Pyridam Farma Tbk (PYFA) membukukan pendapatan Rp2,06 triliun hingga kuartal III-2025, naik 77,3% YoY. EBITDA melonjak 100,6% didorong ekspansi pabrik Probiotec Australia dan penguatan segmen CDMO, NCE, serta OTC.","breadcrumb":{"@id":"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/#primaryimage","url":"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/02\/pyridam-farma-PYFA.webp","contentUrl":"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/02\/pyridam-farma-PYFA.webp","width":1200,"height":801,"caption":"PYFA"},{"@type":"BreadcrumbList","@id":"https:\/\/regular-investor.com\/index.php\/2025\/11\/05\/pyfa-catat-pendapatan-rp206-triliun-di-kuartal-iii-2025-ebitda-naik-100-didukung-ekspansi-global\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/regular-investor.com\/"},{"@type":"ListItem","position":2,"name":"PYFA Catat Pendapatan Rp2,06 Triliun di Kuartal III-2025, EBITDA Naik 100% Didukung Ekspansi Global"}]},{"@type":"WebSite","@id":"https:\/\/regular-investor.com\/#website","url":"https:\/\/regular-investor.com\/","name":"Regular-investor.com","description":"You Sleep and Makes Money","publisher":{"@id":"https:\/\/regular-investor.com\/#organization"},"alternateName":"R-INVESTOR","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regular-investor.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/regular-investor.com\/#organization","name":"Regular-investor.com","alternateName":"R-INVESTOR","url":"https:\/\/regular-investor.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/regular-investor.com\/#\/schema\/logo\/image\/","url":"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/03\/cropped-Photoroom-20250309_055542.png","contentUrl":"https:\/\/regular-investor.com\/wp-content\/uploads\/2025\/03\/cropped-Photoroom-20250309_055542.png","width":512,"height":512,"caption":"Regular-investor.com"},"image":{"@id":"https:\/\/regular-investor.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/regularinvestorscom","https:\/\/x.com\/rinvestorcom","https:\/\/www.instagram.com\/regularinvestorcom\/"]},{"@type":"Person","@id":"https:\/\/regular-investor.com\/#\/schema\/person\/e0935cf1dd7abe3c6dc3ba60c4c6afbf","name":"Septian","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/92a9de20d2caa2c476ece696d5c701129c727d67c38aec458c129ecec23aeb40?s=96&d=wavatar&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/92a9de20d2caa2c476ece696d5c701129c727d67c38aec458c129ecec23aeb40?s=96&d=wavatar&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/92a9de20d2caa2c476ece696d5c701129c727d67c38aec458c129ecec23aeb40?s=96&d=wavatar&r=g","caption":"Septian"}}]}},"jetpack_publicize_connections":[],"_links":{"self":[{"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/posts\/6708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/comments?post=6708"}],"version-history":[{"count":1,"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/posts\/6708\/revisions"}],"predecessor-version":[{"id":6709,"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/posts\/6708\/revisions\/6709"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/media\/5244"}],"wp:attachment":[{"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/media?parent=6708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/categories?post=6708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regular-investor.com\/index.php\/wp-json\/wp\/v2\/tags?post=6708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}